Technology Commercialization Office

Showing 1 result(s) for "Infectious Diseases"



Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.